公开(公告)号：US08981065B2

公开(公告)日：2015-03-17

申请号：US13936486

申请日：2013-07-08

Applicant: Novo Nordisk A/S—Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C12P21/08 ,  C07K16/00 ,  C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US11365393B2

公开(公告)日：2022-06-21

申请号：US15876839

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Alessandro Moretta ,  Mariella Della Chiesa

IPC: A61K39/00 ,  C12N5/0783 ,  C07K16/28 ,  G01N33/569 ,  A61K9/127

Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20180216069A1

公开(公告)日：2018-08-02

申请号：US15876839

申请日：2018-01-22

Applicant: INNATE PHARMA

Inventor： Alessandro Moretta ,  Mariella Della Chiesa

IPC: C12N5/0783

Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20150344576A1

公开(公告)日：2015-12-03

申请号：US14829170

申请日：2015-08-18

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。

公开(公告)号：US20150191547A1

公开(公告)日：2015-07-09

申请号：US14659045

申请日：2015-03-16

Applicant: Novo Nordisk A/S - Novo Alle ,  Innate Pharma S.A.S. ,  University of Genoa

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Louis Spee ,  Michael Wilken

IPC: C07K16/42

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

公开(公告)号：US20130287770A1

公开(公告)日：2013-10-31

申请号：US13936486

申请日：2013-07-08

Applicant: INNATE PHARMA S.A.S. ,  NOVO-NORDISK A/S - NOVO ALLE

Inventor： Alessandro Moretta ,  Mariella Della Chiesa ,  Pascale Andre ,  Laurent Gauthier ,  Francois Romagne ,  Peter Andreas Nicolai Reumert Wagtmann ,  Ivan Svendsen ,  Stefan Zahn ,  Anders Svensson ,  Matthias Thorolfsson ,  Soren Berg Padkaer ,  Kristian Kjaergaard ,  Pieter Johannes Loius Spee ,  Milchael Wilken

IPC: C07K16/28

CPC classification number: C07K16/42 ,  C07K16/28 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。